Jack Allen ツイート
The effectiveness of blood Tumor Mutational Burden (bTMB) may play a key role in $BMY strategy for their IO portfolio (Opdivo/Yervoy) moving forward
↓
BMS：TMBバイオマーカーFoundation Medicineの研究(ロシュ）
nature medicine 8/6/2018
Foundation Medicine
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
Jack Allen ツイート
The effectiveness of blood Tumor Mutational Burden (bTMB) may play a key role in $BMY strategy for their IO portfolio (Opdivo/Yervoy) moving forward
↓
BMS：TMBバイオマーカーFoundation Medicineの研究(ロシュ）
nature medicine 8/6/2018
Foundation Medicine
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab